Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

The Hydroponics Company Ltd granted a cannabis research licence

The licence allows Canndeo to build its exclusive Plant Breeders Rights.
The Hydroponics Company Ltd issued a cannabis research licence
Dr Andrew Beehag, CEO of Canndeo, recently presenting to investors

The Hydroponics Company (ASX:THC) is one of the first ASX-listed cannabis companies to have secured a medicinal cannabis research licence.

The license was granted to THC’s wholly owned subsidiary Canndeo Ltd by the Office of Drug Control.

The research licence will allow Canndeo to build its exclusive Plant Breeders Rights (PBR) protected Cannabis sativa strains.

Dr Andrew Beehag, chief executive officer of Canndeo, commented:

"We are very pleased to have been issued a research licence, which effectively paves the way forward for future domestic supply of medicinal cannabis, targeting multiple markets with high purity cannabidiol (CBD) and enabling THC to continue its roll out of high quality imported products as well as locally produced medicines."


Analysis

THC will now advance research into medicinal cannabis to undertake both its own research exploring optimal cultivation and production methodologies and strain development.

The company will also look to the implementation of its epigenetic technology as a key innovation in the field.

The research licence is the first step in establishing Canndeo’s domestic pharmaceutical production capability with anticipated product availability in 2018.

THC has been one of the most successful IPO's of 2017, and shares are expected to open higher today.

The heavily oversubscribed IPO was priced at $0.20 per share, with the company last trading at $0.31 per share.

Join our Crypto, Blockchain and Cannabis Telegram group here
View full THC profile View Profile

The Hydroponics Company Ltd Timeline

Related Articles

cannabis leaf and green tablets
October 29 2018
The company will now proceed with stage II of the human clinical trial.
medical cannabis
October 01 2018
The companies will collaborate on activities to develop cannabinoid medicines as a medical option in Chile.
Woman holding cannabis leaf
October 16 2018
Canadian subsidiary Crystal Mountain is expanding its range of hydroponics equipment to meet expected demand.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use